| Literature DB >> 34420747 |
Milad Ashrafizadeh1, Sepideh Mirzaei2, Mohammad Hossein Gholami3, Farid Hashemi4, Amirhossein Zabolian5, Mehdi Raei6, Kiavash Hushmandi7, Ali Zarrabi8, Nicolas H Voelcker9, Amir Reza Aref10, Michael R Hamblin11, Rajender S Varma12, Saeed Samarghandian13, I J Arostegi14, M Alzola14, Alan Prem Kumar15, Vijay Kumar Thakur16, Noushin Nabavi17, Pooyan Makvandi18, Franklin R Tay19, Gorka Orive20.
Abstract
An important motivation for the use of nanomaterials and nanoarchitectures in cancer therapy emanates from the widespread emergence of drug resistance. Although doxorubicin (DOX) induces cell cycle arrest and DNA damage by suppressing topoisomerase activity, resistance to DOX has severely restricted its anti-cancer potential. Hyaluronic acid (HA) has been extensively utilized for synthesizing nanoparticles as it interacts with CD44 expressed on the surface of cancer cells. Cancer cells can take up HA-modified nanoparticles through receptor-mediated endocytosis. Various types of nanostructures such as carbon nanomaterials, lipid nanoparticles and polymeric nanocarriers have been modified with HA to enhance the delivery of DOX to cancer cells. Hyaluronic acid-based advanced materials provide a platform for the co-delivery of genes and drugs along with DOX to enhance the efficacy of anti-cancer therapy and overcome chemoresistance. In the present review, the potential methods and application of HA-modified nanostructures for DOX delivery in anti-cancer therapy are discussed.Entities:
Keywords: CD44; Doxorubicin; Drug resistance; Endocytosis; Hyaluronic acid; Nanodelivery system; Theranostic
Mesh：
Substances：
Year: 2021 PMID： 34420747 DOI： 10.1016/j.carbpol.2021.118491
Source DB: PubMed Journal: Carbohydr Polym ISSN： 0144-8617 Impact factor: 9.381